Investor Presentation for Q4 FY 2025-26
ANUHPHR · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Anuh Pharma reported FY26 revenue of Rs. 776 Cr, up 15.66% YoY, driven by strong volume growth and expansion into regulated markets. The company achieved record production of 1,733 MT (up 25% YoY) with capacity expanded to 2,400 MTPA. However, profitability metrics declined: EBITDA margin fell from 10.64% to 8.56%, and net profit margin dropped from 7.16% to 5.32%, with PAT down 13.32% to Rs. 41.05 Cr. Q4 showed sequential improvement with EBITDA up 18.32% QoQ. The company successfully completed USFDA and EU GMP inspections with zero 483 observations, reinforcing quality compliance. Export contributed 46% of revenue with Africa (33%), Europe (24%), and Asia (35%) as key markets.
Despite strong revenue growth, margin compression is a concern for shareholders. The company remains focused on regulated markets and capacity expansion, targeting 15-20% annual growth, but profitability recovery will be key to watch.